Show simple item record

dc.contributor.authorMakawita, S
dc.contributor.authorAbou-Alfa, GK
dc.contributor.authorRoychowdhury, S
dc.contributor.authorSadeghi, S
dc.contributor.authorBorbath, I
dc.contributor.authorGoyal, L
dc.contributor.authorCohn, A
dc.contributor.authorLamarca, Angela
dc.contributor.authorOh, DY
dc.contributor.authorMacarulla, T
dc.contributor.authorShroff, RT
dc.contributor.authorHowland, M
dc.contributor.authorLi, A
dc.contributor.authorCho, T
dc.contributor.authorPande, A
dc.contributor.authorJavle, M
dc.date.accessioned2020-08-10T08:09:21Z
dc.date.available2020-08-10T08:09:21Z
dc.date.issued2020en
dc.identifier.citationMakawita S, G KA-A, Roychowdhury S, Sadeghi S, Borbath I, Goyal L, et al. Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future Oncol. 2020.en
dc.identifier.pmid32580579en
dc.identifier.doi10.2217/fon-2020-0299en
dc.identifier.urihttp://hdl.handle.net/10541/623097
dc.description.abstractCholangiocarcinoma is an aggressive malignancy with poor overall survival. Approximately 15% of intrahepatic cholangiocarcinomas contain FGFR alterations. Infigratinib is an oral FGFR 1-3 kinase inhibitor. Favorable results from a Phase II trial of infigratinib in advanced/metastatic FGFR-altered cholangiocarcinomas has led to its further investigation in the front-line setting. In this article we describe the design, objectives and rationale for PROOF 301, a Phase III multicenter, open label, randomized trial of infigratinib in comparison to standard of care gemcitabine and cisplatin in advanced/metastatic cholangiocarcinoma with FGFR2 translocations. The results of this study have the potential to define a new role for a chemotherapy-free, targeted therapy option in the front-line setting for these patients. Clinical Trial Registration: NCT03773302 (ClincalTrials.gov). Keywords: cholangiocarcinoma; fibroblast growth factor receptor inhibitor; infigratinib; targeted therapy.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.2217/fon-2020-0299en
dc.titleInfigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trialen
dc.typeArticleen
dc.contributor.departmentDivision of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX 77030, USA.en
dc.identifier.journalFuture Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record